Global Pulmonary Arterial Hypertension Market Share

Statistics for the 2023 & 2024 Global Pulmonary Arterial Hypertension market share, created by Mordor Intelligence™ Industry Reports. Global Pulmonary Arterial Hypertension share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Pulmonary Arterial Hypertension Industry

The Pulmonary Arterial Hypertension Market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. The leading players in the global market for Pulmonary Arterial Hypertension are - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

Pulmonary Arterial Hypertension (PAH) Market Leaders

  1. Bayer AG

  2. Gilead Sciences, Inc.

  3. Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)

  4. Pfizer, Inc.

  5. United Therapeutics Corporation

*Disclaimer: Major Players sorted in no particular order

Pulmonary Arterial Hypertension Market Concentration

Pulmonary Arterial Hypertension Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)